NorthlineHealth
Join
← FormularyTracking · Category 2

Anti-inflammatory Tripeptide · α-MSH Fragment

KPV

Anti-inflammatory

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It binds MC1R and intracellular receptors in gut epithelial cells, inhibiting NF-κB signaling and downstream pro-inflammatory cytokine production. Demonstrated gut-protective effects in IBD animal models.

Indications

→Gut inflammation and IBD support
→Systemic anti-inflammatory
→Skin inflammatory conditions
→Wound healing adjunct

Regulatory status

KPV has no FDA approval and is categorized as a Category 2 substance under the 503A framework. Not eligible for routine compounding. Northline monitors reclassification.

References

01Dalmasso G, et al. The peptide KPV has anti-inflammatory effects in murine colitis by downregulating NF-κB activity. J Crohns Colitis. 2013.
02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.